Atom Investors’s Antares Pharma, Inc. ATRS Stock Holding History

Atom Investors’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-161,286	Closed	-$444K	–	661
2020 Q2	$444K	Buy	+161,286	New	+$450K	0.03%	282
2019 Q4	–	Sell	-28,020	Closed	-$94K	–	341
2019 Q3	$94K	Buy	+28,020	New	+$92.3K	0.01%	273

Other funds holding ATRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Atom Investors's ATRS Position: Q3 2020 in Review

Atom Investors sold out of Antares Pharma, Inc. (ATRS) in Q3 2020, closing a stake of 161,286 shares — an estimated $444K sold.

Atom Investors first reported a position in ATRS in Q3 2019 and held it in 2 quarters. The position peaked at $444K in Q2 2020. 164 funds tracked by Wall St. Rank hold ATRS as of Q3 2020.

Atom Investors reported no remaining Antares Pharma, Inc. position as of Q3 2020 after selling out during the quarter.
Atom Investors sold 161,286 Antares Pharma, Inc. shares in Q3 2020, an estimated $444K.
Atom Investors first reported a position in Antares Pharma, Inc. in Q3 2019 and held it in 2 quarters.
Atom Investors's Antares Pharma, Inc. position peaked at $444K in Q2 2020.
164 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q3 2020.

Based on Atom Investors's 13F filing for Q3 2020, filed 13 Nov 2020.